Accueil   Diary - News   All news Theranexus announces inclusion of the last patient in phase II trial of drug candidate THN102 against narcolepsy

Theranexus announces inclusion of the last patient in phase II trial of drug candidate THN102 against narcolepsy

 

 

Lyon, 29 October 2018 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, announces today that it has recruited the last patient in its Phase II trial, entitled "Tolerance and Efficacy of THN102 on Sleepiness in Narcoleptic Patients". A total of 48 patients were recruited across seven centers in France and Belgium under the coordination of Professor Yves Dauvilliers, the trial’s Principal Investigator, based at the Montpellier Regional University Hospital’s National Reference Center for Narcolepsy.

 

Read the press release